Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Antiretroviral agent
Original Date: 
August 2005
Revised Date: 
December 2019
  • Prophylaxis or treatment  of human immunodeficiency virus (HIV) infections
Reconstitution and Stability: 
  • 10 mg/mL  solution
  • Store unopened vials at room temperature:  protect from light
  • Diluted solutions (D5W, NS) stable 8 days at room temperature or refrigerated.  Since product contains no preservative, manufacturer recommends administration within 8 hours if stored at room temperature or 24 hours if refrigerated

- Solutions Compatible: D5W, NS

- Additive/Above Cassette Compatible: no information

- Y-site Compatible: morphine, KCl, TPN (amino acids/dextrose), vancomycin

- Incompatible: no information


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct NO
IV Intermittent Infusion YES
Usual dilution: 1 mg/mL
Infusion time: 30 minutes to 1 hour
IV Continuous Infusion YES
Usual dilution: 1 mg/mL




(For neonatal dosages, refer to Neonatal IV Drug Manual.)

 Term neonates and infants < 6 weeks

  • 3 mg/kg/dose IV Q12H for a total of 6 weeks of therapy
Potential hazards of parenteral administration: 
  • Headache, myalgia, nausea, insomnia may occur; often worse during the first two weeks of therapy and usually subside after that
  • Granulocytopenia, anemia
  • Hepatomegaly, elevated serum AST, LDH and alkaline phosphatase

Adverse Effects:                                                                        

  • Dose related anemia, leukopenia, neutropenia, occurs in up to 30% of patients                 
  • Onset anemia 2-4 weeks; granulocytopenia 6-8 weeks
  • Appears to be related to pretreatment bone marrow reserve, dose and duration or therapy
  • Dose adjustment, dose interruption, and/or transfusion may be required
  • Hematologic toxicity may be additive with other bone marrow suppressive agents
  • DO NOT administer IM or by intravenous push
  • Monitor CBC with differential, platelets, hemoglobin, MCV, reticulocyte count, serum creatine kinase, CD4 cell count, HIV RNA plasma levels, renal and hepatic function tests

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.